NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors), SIRT1 stimulants(NAD-dependent deacetylase sirtuin 1 stimulants), SIRT5 agonists(NAD-dependent protein deacetylase sirtuin-5 agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseCardiovascular Diseases+ [10]

Active Indication

Parkinson DiseaseAcidosis, LacticAlzheimer Disease+ [16]

Inactive Indication

Colorectal CancerInfertilityLiver metastases+ [2]

Originator Organization

medilabo RFP, Inc.

EvoNext Holdings SA

Active Organization

The Affiliated Hospital of Guizhou Medical University

Protheragen, Inc.

medilabo RFP, Inc.

+ [11]

Inactive Organization

Sirtris Pharmaceuticals, Inc.

GSK PlcIVI Madrid SL

+ [2]

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC14H12O3

InChIKeyLUKBXSAWLPMMSZ-OWOJBTEDSA-N

CAS Registry501-36-0

277

Clinical Trials associated with Resveratrol

NCT07868458

/ CompletedPhase 4IIT

Randomized, Controlled Study to Investigate the 12-month Efficacy and Safety of Resveratrol Vitamin Supplements in Patients With Non-proliferative Diabetic Retinopathy Without Center Involved Diabetic Macular Edema

This randomized, controlled study aims to investigate the efficacy and safety of resveratrol-containing vitamin supplements in patients with non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (DME).
Patients with diabetes mellitus and NPDR attending the Second Department of Ophthalmology will be enrolled and randomly assigned to a supplementation or control group. During the 12-month follow-up period, the study will evaluate the potential effects of resveratrol supplementation on diabetic retinopathy, including changes in disease severity and progression, while also monitoring its safety and tolerability.

Start Date30 Sep 2026

Sponsor / Collaborator

National & Kapodistrian University of Athens

NCT07592767

/ RecruitingPhase 2IIT

Multicenter, Randomized, Double Blind, Placebo-Controlled Phase 2a Study, to Evaluate Safety, Tolerability and Pharmacokinetics of Resveratrol (JOTROLTM) in Parkinson's Disease

This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.

Start Date17 Sep 2026

Sponsor / Collaborator

Georgetown University Hospital

[+1]

RBR-4cdm4k4

/ Not yet recruitingNot Applicable

Effect of different doses of trans-resveratrol on pain in women with lipedema

Start Date10 Jul 2026

Sponsor / Collaborator-

100 Clinical Results associated with Resveratrol

100 Translational Medicine associated with Resveratrol

100 Patents (Medical) associated with Resveratrol

24,356

Literatures (Medical) associated with Resveratrol

01 Feb 2027·TISSUE & CELL

The synergistic effects of resveratrol and nicotinamide on cell proliferation, apoptosis, and SIRT1 gene expression in human retinal pigment epithelial cells

Article

Author: Keskin, Tuğba ; Yucel, Ozlem Eski ; Tural, Sengul

The aim of our study is to evaluate the effects of Resveratrol and Nicotinamide on cell proliferation, viability, apoptosis and SIRT1 gene expression in human retinal pigment epithelial cells (RPE), with relevance to age-related macular degeneration (AMD). Healthy RPE cells were exposed to moderate oxidative stress, then treated with resveratrol (50-100-150 μmol/L) and nicotinamide (1-5-10 mM/L), both separately and in combination, for 24, 48, and 72 h. Morphological changes and cell density were examined using inverted microscopy to complement functional data. The most significant results were achieved with 72 h of combined treatment with 100 μmol/L resveratrol and 1 mM/L nicotinamide, showing increased cell viability and proliferation (p < 0.001), decreased apoptosis+necrosis values (p < 0.001), and elevated SIRT1 expression (p < 0.001). This combination was non-cytotoxic to healthy RPE cells (p > 0.05) and more effective than separate treatments. The combined application caused SIRT1 gene expression levels similar to healthy controls (p > 0.05). To confirm functional dependency on SIRT1, targeted gene silencing was performed using SIRT1 siRNA. Compared to the negative control group, SIRT1 silencing resulted in a 25.58-fold downregulation of SIRT1 mRNA, accompanied by a 5.28-fold upregulation of pro-apoptotic Bax and a 3.91-fold downregulation of anti-apoptotic Bcl-2 (p < 0.001), effectively reversing the cytoprotective effects of the co-treatment. These findings demonstrate that RV+NAM co-treatment exerts robust synergistic protection against oxidative stress-induced apoptosis in RPE cells through SIRT1-dependent mechanism, offering a promising therapeutic strategy for dry AMD. This is the first study to investigate the effects of this specific dose combination in a dry AMD model.

01 Feb 2027·TISSUE & CELL

Resveratrol attenuates oxidative stress in chronic obstructive pulmonary disease by Nrf2-mediated inhibition of ferroptosis

Article

Author: Wu, Jie ; Wan, Shijin ; Tang, Bin ; Huang, Yaqi ; Zhu, Wenyan ; Liu, Na

BACKGROUND:

Oxidative stress and ferroptosis contribute to cigarette smoke (CS)-related epithelial injury in chronic obstructive pulmonary disease (COPD), but the extent to which resveratrol (RES) modulates this process through Nrf2 remains incompletely defined.

METHODS:

We used a CS plus lipopolysaccharide-induced mouse model and CSE-stimulated BEAS-2B cells. Lung histopathology, BALF inflammation, oxidative stress indices, ferroptosis-related markers, C11-BODIPY lipid peroxidation, Nrf2/HO-1 signaling, and public COPD transcriptomic data were analyzed. ML385 was applied to pharmacologically inhibit Nrf2 in vitro.

RESULTS:

RES attenuated lung injury and inflammatory infiltration, restored GSH, and reduced MDA, Fe2 + , and 4-HNE accumulation. RES also decreased ferroptosis-associated gene expression and restored Nrf2, HO-1, GPX4, and SLC7A11 expression. In BEAS-2B cells, RES improved viability and reduced lipid peroxidation after CSE exposure, whereas ML385 partially reversed these effects. Transcriptomic analysis supported enhanced oxidative stress/ferroptosis activity and altered Nrf2-related signaling in COPD samples.

CONCLUSION:

RES mitigates COPD-related oxidative stress and ferroptosis, at least partly through Nrf2-associated antioxidant signaling. These findings support further investigation of the Nrf2-ferroptosis network as a therapeutically relevant pathway in COPD.

01 Feb 2027·EXPERIMENTAL NEUROLOGY

A critical mechanistic synthesis of PINK1-mediated mitophagy signaling and its therapeutic targeting in Parkinson's disease neurodegeneration

Review

Author: Zawiah, Mohammed ; Imran, Mohd ; Khan, Abida ; Bakht, Md Afroz ; Rehman, Zia Ur ; Jawaid, Talha ; Shakeel, Faiyaz ; Alshammari, Mohammed Kanan

Parkinson's disease (PD) is a progressive neurodegenerative disorder that is associated with loss of dopaminergic neurons, mitochondrial dysfunction and disruption of cellular homeostasis. PTEN-induced kinase 1 (PINK1) plays a crucial role in mitochondrial quality control by regulating mitophagy, mitochondrial dynamics, and calcium signaling to maintain neuronal bioenergetic homeostasis. This review critically evaluates the molecular pathways underlying PINK1-mediated mitochondrial integrity and the mechanisms by which loss-of-function mutations contribute to the pathogenesis of PD. Familial early-onset PD is strongly associated with pathogenic PINK1 mutations identified through genetic studies. Therapeutic approaches targeting the PINK1 pathway are examined, including adeno-associated virus (AAV)-based gene delivery, direct small-molecule PINK1 activation (MTK458), and indirect modulation of mitophagy and mitochondrial homeostasis by compounds such as curcumin, resveratrol, cannabidiol, gastrodin, and quercetin. Moreover, the complementary restoration of mitochondrial homeostasis through the modulation of downstream targets, such as transcription factor EB (TFEB) activation and BCL2-interacting protein 3-like (BNIP3L/NIX)-mediated mitophagy, is discussed as an indirect therapeutic strategy. Another important finding is that PD is a biologically and clinically heterogeneous disease that requires biomarker-directed and genotype-stratified therapeutic development. Finally, major translational issues are critically evaluated, including challenges related to blood-brain barrier penetration, target specificity, and long-term safety of mitochondrial modulators.

News (Medical) associated with Resveratrol

06 Oct 2026

·www.biospace.com

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value

First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL ™ in Patients with Parkinson’s Disease Tungsten Advisors has been retained to identify strategic options to monetize Jupiter’s existing clinical development programs via corporate partners and explore other strategic options for a transaction to maximize shareholder value Jupiter, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that the first patient has been dosed in the company’s Phase 2a RESET clinical trial evaluating JOTROL ™ in patients with Parkinson’s disease (PD). The dosing of the first patient represents an important clinical milestone for Jupiter and marks the transition of JOTROL ™ into Phase 2a clinical evaluation in patients with Parkinson’s disease. The RESET study ( NCT07592767 ) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and biomarker effects of JOTROL ™ , Jupiter’s investigational, proprietary micellar formulation of trans-resveratrol. “Dosing the first patient in RESET is a significant milestone for Jupiter and the culmination of years of scientific, regulatory and clinical development work,” said Christer Rosén, Chief Executive Officer of Jupiter Neurosciences. “We believe that JOTROL has the potential to address biological pathways implicated in Parkinson’s disease, including mitochondrial dysfunction, oxidative stress and neuroinflammation. With patient dosing now underway, we look forward to advancing enrollment and generating clinical data that will help us evaluate JOTROL’s potential in this significant area of unmet medical need.” RESET is expected to enroll approximately 30 patients with Parkinson’s disease who will be randomized 1:1:1 to receive one of two dose levels of JOTROL ™ or placebo. Study treatment will be administered orally for 12 weeks. The trial’s primary objectives include assessment of safety, tolerability and pharmacokinetics, including evaluation of JOTROL ™ exposure in plasma and cerebrospinal fluid. Secondary and exploratory assessments include biomarkers associated with energy metabolism, inflammation and Parkinson’s disease, as well as clinical outcome measures. “The first patient dosed in RESET represents an important step in translating the scientific rationale for JOTROL into a clinical study in people living with Parkinson’s disease,” said the study’s principal investigator Fernando L. Pagan, MD, professor of neurology at Georgetown University School of Medicine and Vice Chairman of the Department of Neurology. Georgetown University is the study sponsor. “This study is designed to provide important information regarding JOTROL’s safety, pharmacokinetics and biological activity in Parkinson’s disease and to help inform the future clinical development of the program.” JOTROL ™ is designed to overcome limitations associated with the bioavailability of conventional resveratrol. In a completed Phase 1 study in healthy volunteers, JOTROL ™ demonstrated increased systemic exposure to resveratrol and measurable cerebrospinal fluid concentrations. The Phase 1 study reported no serious adverse events. Preclinical studies in a model of Parkinson’s disease also demonstrated neuroprotective effects, including improvements in measures of motor function. These findings supported advancement of JOTROL ™ into the RESET Phase 2a study. “Moving from enrollment to dosing our first patient is a defining moment for Jupiter and, importantly, puts us in a position to begin generating patient data from our lead clinical program,” said Alison Silva, President and Chief Business Officer of Jupiter Neurosciences. “We are grateful to the patients, investigators, clinical sites and collaborators participating in RESET. We remain focused on efficient execution of the study and look forward to providing updates as the program progresses.” As the company continues to enroll patients in the RESET trial, it has also initiated a formal process to explore and evaluate strategic options to maximize shareholder value. These options may include the sale or licensing of clinical and other assets, strategic partnerships, business combinations, or other corporate transactions. Jupiter has engaged Tungsten Advisors as the company's strategic advisor. There can be no assurance that this process will result in any transaction. Jupiter does not intend to provide updates regarding the process unless and until its Board of Directors approves a specific transaction or the Company otherwise determines that disclosure is appropriate or required. About Parkinson’s Disease Market 1.1 million U.S. patients living with Parkinson’s Disease 90,000 new U.S. diagnoses annually; 1.2 million U.S. patients projected by 2030 $82.2 billion annual U.S. economic burden of Parkinson’s Disease ~90% of PD patients are Medicare-enrolled No disease-modifying therapies currently approved for PD; multiple investigational candidates are in active development by other companies Global PD treatment market: $5.65B (2024) → $7.58B (2030), CAGR 5.04% Global prevalence: >10 million patients (18)30295-3 About the RESET Trial RESET (RESvEraTrol in Parkinson’s Disease) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating JOTROL ™ in approximately 30 patients with Parkinson’s disease. Participants are randomized to receive one of two doses of JOTROL ™ or placebo over a 12-week treatment period. The study is designed primarily to evaluate safety, tolerability and pharmacokinetics and will also examine pharmacodynamic and disease-relevant biomarkers, including measures associated with mitochondrial function, energy metabolism and inflammation. Exploratory clinical assessments are intended to provide additional information to inform the design of future JOTROL ™ clinical studies. Additional information regarding RESET is available at ClinicalTrials.gov under identifier NCT07592767. Dr. Charbel Moussa, a sub-investigator on this study at Georgetown University, has financial interests related to Jupiter Neurosciences. About JOTROL ™ JOTROL ™ is Jupiter Neurosciences’ proprietary and patented micellar formulation of trans-resveratrol designed to improve the bioavailability of resveratrol. Resveratrol has been extensively studied for its potential effects on biological pathways associated with oxidative stress, inflammation and mitochondrial function. Jupiter is developing JOTROL ™ as an investigational therapeutic candidate for neurodegenerative and rare diseases. JOTROL ™ is an investigational drug candidate and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Its safety and efficacy for the treatment of Parkinson’s disease or any other disease have not been established. About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL TM - a proprietary, enhanced bioavailability resveratrol formulation - is currently in a Phase 2a clinical trial for Parkinson's disease. JUNS also commercializes Nugevia TM , a consumer longevity supplement. Additionally, the Company’s pipeline includes ALA-002, a next-generation, patented psychedelic new chemical entity (NCE) recently in-licensed from PharmAla Biotech Holdings. For more information, please visit . Forward-Looking Statements Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, without limitation, statements regarding the company’s pursuit of strategic options; patient enrolment and dosing timelines for the Phase 2a RESET trial; expected study completion dates; expected development timelines; and potential regulatory pathways. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, that clinical trials may not demonstrate adequate safety or tolerability; enrolment may be slower than anticipated; preliminary data may not be predictive of future results; the company’s inability to identify or consummate strategic opportunities on the terms contemplated or at all; and other risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 filed on April 1, 2026 and any subsequent quarterly reports. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements. We assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Investor Relations Contact Jupiter Neurosciences, Inc. Christer Rosen, Chairman & Chief Executive Officer ir@jupiterneurosciences.com

Phase 2Phase 1Clinical Result

25 Aug 2026

·www.prnewswire.com

Agency Skin Announces Breakthrough Approach to Skin Longevity With New Personalized, Patent-Pending Treatments

New prescription treatments, advanced ingredients, and personalized dermatological care to target skin longevity at the biological core SAN DIEGO, Aug. 25, 2026 /PRNewswire/ -- Agency Skin™, a leader in personalized prescription skincare, today launched its next generation of treatments for skin longevity, debuting a new line of innovative prescription formulas and a patent-pending Skin Smoothing Booster™ featuring an exclusive seven-peptide blend. Continue Reading Agency Skin 2026 Developed by its board-certified dermatologists and scientists, Agency Skin's treatments combine advanced, science-backed ingredients including tretinoin, vitamin C, estriol, rapamycin, hydroquinone, and resveratrol to address the interconnected biological processes associated with visible skin aging. Every patient's prescription formulas and regimen are customized by a licensed medical provider based on their individual needs, goals, medical history, and response to treatment over time. "Driving real results starts with understanding the skin's underlying biology," said Whitney Tolpinrud, MD, FAAD, Board-Certified Dermatologist and Medical Director at Agency Skin. "Two people may have similar concerns about fine lines, firmness, pigmentation, or texture and still need very different treatments. We can personalize not only the prescription actives we prescribe, but their combinations and strengths, and continue to adjust a patient's treatment as their needs change." Agency Skin's New Patent-Pending Prescription Treatments Agency Skin's new prescription lineup addresses multiple signs of visible aging through treatments a licensed medical provider can calibrate with precision, personalizing not just which ingredients to prescribe, but their combinations and strengths for each patient. Agency Night Renew Rx The foundation of Agency Skin's nighttime regimen, Night RenewRx is formulated to target fine lines, firmness, uneven tone, and texture with active ingredients that support cellular turnover and collagen production. Each Night RenewRx formula is tailored by an Agency Skin licensed medical provider with up to four active ingredients. Individual ingredients may include tretinoin, estriol, tranexamic acid, niacinamide, azelaic acid, glycerin, and dexpanthenol. Night RenewRx offers a broad range of tretinoin strengths, including incremental strengths between commonly available doses, from up to 40% stronger and 80% gentler than typical retail pharmacy options. This gives medical providers greater flexibility to personalize treatments based on a patient's skin, goals, and tolerance. Agency Day Defender Rx Day DefenderRx is a personalized daytime antioxidant prescription treatment, developed to help defend against oxidative stress and the visible effects associated with environmental stressors, like UV light and pollution. The formula combines four antioxidants: L-ascorbic acid, or vitamin C, prescribed at concentrations ranging from 10% to 25%, with resveratrol, EGCG (epigallocatechin gallate) derived from green tea, and niacinamide. It is designed to complement nighttime treatment while helping improve the appearance of uneven tone and dullness. Agency Cell Repair Rx Cell RepairRx brings rapamycin, an emerging ingredient in longevity science, into Agency Skin's prescription treatment offerings. The patent-pending formula combines rapamycin and resveratrol, designed to target inflammaging while supporting firmer skin and improved elasticity. Rapamycin calms mTOR — a signaling protein that becomes overactive with age — to reduce inflammation and help cells repair themselves more efficiently. Cell RepairRx is designed as a nightly addition to a patient's Agency Skin regimen. Agency Dark Spot Rx Dark SpotRx is specifically formulated to address hyperpigmentation, including sunspots and melasma, by targeting excess pigment production. Each prescription draws from a range of proven and advanced active ingredients, including hydroquinone in strengths up to 3x higher than typical retail pharmacy options. Additional available actives include azelaic acid, kojic acid, resveratrol, EGCG (epigallocatechin gallate), and hydrocortisone. Agency Eye Revive Rx Developed specifically for the delicate eye area, Eye ReviveRx is a customized nighttime prescription treatment designed to visibly brighten the under-eye area and smooth the appearance of fine lines and crow's feet. Eye ReviveRx formulas contain a precise blend of carefully calibrated ingredients, which may include tretinoin along with ingredients such as dexpanthenol, caffeine, EGCG, and glycerin. Agency Skin's New Regimen Essentials Agency Skin Smoothing Booster (non-Rx) Skin Smoothing Booster is a patent-pending serum powered by an exclusive blend of seven peptides designed to support natural collagen and elastin, visibly smooth fine lines, and complement Agency Skin's personalized prescription treatments. The advanced peptide complex includes 0.5% pure copper peptide GHK-Cu, which gives the serum its distinctive blue hue. Five forms of hyaluronic acid, together with urea and polyglutamic acid, provide multilayer hydration to help leave skin feeling deeply hydrated, plump, and smooth. Together, these advanced ingredients support smoother, healthier-looking skin over time. The Science Behind Agency Skin's Approach to Longevity Agency Skin's new treatments are developed around five interconnected biological pathways associated with visible skin aging: protein degradation, inflammation, cellular repair, oxidative stress, and DNA damage. Each formula is specifically designed around a primary pathway, with secondary support across the others, reflecting the interconnected biology of skin aging. "Skin aging is extraordinarily complex. There isn't one pathway, one ingredient, or one treatment that determines how we age or how we treat it," said Felipe Jimenez, PhD, Head of Scientific Innovation at Agency Skin. "We developed these formulations to address multiple biological processes associated with visible aging, using ingredients that work in complementary ways across a patient's regimen. Personalization allows us to determine not simply which ingredients to use, but how to combine them and at what strengths for an individual patient." The Five Biological Pathways Protein Degradation: Collagen and elastin are essential to firmness, structure, and elasticity. With age, their production and integrity decline, contributing to fine lines, wrinkles, and loss of firmness. Inflammation : Persistent low-grade inflammation, often referred to as "inflammaging," can contribute to collagen and elastin degradation and impaired barrier function. Cellular Repair: Natural renewal and repair processes become less efficient with age, affecting resilience, recovery, texture, and other visible characteristics of healthy-looking skin. Oxidative Stress: UV exposure, pollution, and other environmental stressors generate free radicals that can cause cellular damage and contribute to dullness, uneven tone, and premature visible aging. DNA Damage: Daily exposure, particularly to UV radiation, can cause DNA damage. As damage accumulates and repair mechanisms become less efficient with age, it can disrupt normal skin function and contribute to visible signs of aging. Personalized Dermatological Care, Built Around the Patient The foundation of Agency Skin's model is an ongoing relationship between every patient and a licensed medical provider. Each treatment plan begins with an online medical consultation, during which the provider determines the appropriate prescriptions, ingredients, combinations, and strengths and builds the patient's regimen around them. Patients can communicate directly with their provider, share progress photos, discuss results or concerns, and request adjustments as their needs change. This allows treatment to evolve based on each patient's response over time. Agency Skin Pricing and Availability Personalized prescription treatments start at $110 for a 60-day supply and are available by subscription following a medical consultation. New patients receive 50% off their first 60-day supply. Agency Skin's non-Rx products start at $40 and can be purchased individually or by subscription. All products are backed by a 120-day money-back guarantee (restrictions apply). Beginning today, all new treatments and products are available at AgencySkin.com. About Agency Skin Agency Skin is a leader in personalized prescription skincare, combining advanced treatments with ongoing care from licensed medical providers. Developed by Agency Skin's dermatologists and scientists, every prescription and regimen is designed to address individual needs and support healthy-looking skin and skin longevity. Agency Skin is headquartered in San Diego, CA and serves patients across the United States. SOURCE Agency Skin 21% more press release views with Request a Demo

12 Aug 2026

·www.einpresswire.com

Demeterherb: A Leading Cosmetic Grade Resveratrol Raw Material Manufacturer from China at CPHI Korea 2026

XI'AN, SHAANXI, CHINA, August 12, 2026 / EINPresswire.com / -- For skincare and supplement developers, sourcing resveratrol is rarely about a single ingredient name. Behind the phrase Cosmetic Grade Resveratrol Raw Material Manufacturer From China sits a fuller procurement question: where the active comes from, what form it takes, which documents arrive with each batch, and whether supply can hold steady across repeat orders. Resveratrol, a plant-derived polyphenol valued for its antioxidant activity, has to enter a formulation file as a defined specification, not a marketing word. Demeterherb , the brand of Xi'an Demeter Biotech Co., Ltd., brings plant extracts, cosmetic ingredients, and related nutrition raw materials under one platform. Its resveratrol line includes water-soluble resveratrol 10%, resveratrol at 50%, 98%, and 99%, and customizable specifications. These options give formulators several entry points for different development paths. That specification-first approach will also shape Demeterherb's CPHI Korea 2026 presence at Stand K33, where pharmaceutical, nutraceutical, and cosmetic buyers can discuss resveratrol grades, sourcing routes, and documentation for their formulation needs. Cosmetic Grade Resveratrol Starts with a Clear Raw-Material Definition The evaluation begins with the material itself. Rather than treating "antioxidant" as a complete product description, buyers should confirm the active ingredient, sourcing route, test method, and documentation. On the Polygonum cuspidatum extract page, cosmetic grade resveratrol is identified as a white powder standardized to 98%, with HPLC listed as the test method. Demeterherb's wider range also includes water-soluble resveratrol 10% and resveratrol at 50% and 99%, while custom specifications can be discussed for project-specific requirements. The same page lists a COA on request and a 24-month shelf life. Clear inputs reduce guesswork when a formulation moves from bench trials toward commercial batches. Two Sourcing Routes Give Formulators a More Specific Starting Point Demeterherb's resveratrol information sets out several specifications and two sourcing routes. Standard resveratrol is available at 50%, 98%, and 99%, while a water-soluble 10% grade supports projects that prioritize dispersion. The botanical extract and fermented Trans-Resveratrol routes should not be read as one specification. Route and stated content together shape how a formulation team builds its shortlist and compares documents. The fermented material is produced through natural microbial fermentation, with stable Trans-Resveratrol as its primary active form, and the product page positions it for premium skincare and supplement formulations. The page also notes that the fermentation route avoids the solvent residues linked to some synthetic processes and supports batch traceability, points that matter to buyers building a clean-label story. That connects grade to end use while leaving unstated details, such as microbial or INCI data not published on the page, out of the decision. Each route maps to its own product page, with the fermented grade carrying CAS 501-36-0, which keeps sample requests and technical follow-up anchored to verifiable pages. Purity, Test Method, and Documentation Form the Quality Review Core Quality review does not end at a single purity number. It rests on the product name, active ingredient, test method, appearance, packaging, and available documents together. On the 98% botanical page, Demeterherb lists these as product parameters and offers practical packing choices: a 1 kg aluminum foil bag, a 25 kg carton, and a 25 kg fiber drum. The fermented grade adds foil bag and drum options with nitrogen flushing and light protection, details that speak to how an antioxidant powder holds up in transit and storage. HPLC is named as the test method, and a COA is available for documented review, alongside MSDS and TDS files that a purchasing team can check against incoming batches. At the company level, Demeterherb states that its factory operates to GMP standards and holds credentials including ISO22000, EU Organic, USDA Organic, Halal, Kosher, and FDA registration. Those enterprise credentials describe the quality system and international footing behind the business; they should be read as company background rather than as an organic claim for the resveratrol powder itself. Cosmetic Ingredient Positioning Extends Beyond a Single Powder Specification The fermented 99% Trans-Resveratrol grade sits within Demeterherb's cosmetic ingredients range and is described directly as a skincare-oriented antioxidant raw material. For a formulator, that placement moves the question from "does it contain resveratrol" to "does this specification fit the skincare system already in development." The product page points to typical uses across serums, creams, and masks, alongside nutrition supplement and functional cosmetic formats, and describes the active as a lipophilic antioxidant meant to support the skin barrier against everyday oxidative stress. Demeterherb also offers OEM and ODM support, so a brand can move from a stock specification toward tailored blending or private-label manufacturing without changing suppliers. Demeterherb has also published technical content on liposomal resveratrol for clean-beauty and longevity formulations, a sign that the company is discussing resveratrol in a liposomal delivery format as well as a standard powder. That material works as an internal reference for technical conversations, while stability, regulatory fit, and finished-product performance stay tied to each target market's requirements and project-level testing. A China-Based Manufacturing Platform Supports International Ingredient Workflows Xi'an Demeter Biotech Co., Ltd. is based in Xi'an, China, and was founded in 2017. Its business spans plant extracts, organic extracts, organic fruit and vegetable powders, natural food colors, and related raw materials, serving pharmaceutical, nutraceutical, nutrition supplement, functional food, functional beverage, and cosmetic companies. That cross-category base is what supports Demeterherb's positioning in the cosmetic raw-material space. The company holds independent import and export rights and works through air, sea, rail, truck, and express logistics partners, with a customer footprint that reaches more than 50 countries across the Americas, Asia, and Europe. For a cosmetic grade resveratrol project, this platform links inquiry, samples, documentation, and bulk delivery into one coordinated flow, and the word "leading" rests on these checkable capabilities rather than an unverified market ranking. CPHI Korea 2026, scheduled for August 25-27 at COEX in Seoul, fits this international ingredient workflow rather than sitting apart from it. Xi'an Demeter Biotech Co., Ltd. is listed at Stand K33, giving buyers a venue to move from resveratrol route and specification questions into sampling, documentation review, and purchasing follow-up. Sourcing Cosmetic Grade Resveratrol with Demeterherb Demeterherb's cosmetic grade resveratrol offering covers water-soluble resveratrol 10%, standard resveratrol at 50%, 98%, and 99%, and customizable specifications. The botanical and fermented routes remain distinct within this range, supporting specification review, formulation development, and document verification for skincare and supplement buyers. Teams evaluating a Trans-Resveratrol powder supplier can request samples, a COA, full specifications, packaging details, and project-level inquiry support through https://www.demeterherb.com/ . The company's guiding promise is straightforward: customer-focused, employees-based, quality-oriented. Xi'an Demeter Biotech Co., Ltd. Demeterherb email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Resveratrol

External Link

KEGG	Wiki	ATC	Drug Bank
-	Resveratrol	-	DB02709

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infertility	Phase 3	Spain	IVI Madrid SL	13 Mar 2018
Ovarian Hyperstimulation Syndrome	Phase 3	Spain	IVI Madrid SL	13 Mar 2018
Multiple Myeloma	Phase 2	Denmark	Sirtris Pharmaceuticals, Inc.	11 Dec 2008
Dementia	Phase 2	-	EvoNext Holdings SA	-
Parkinson Disease	Phase 2	United States	Jupiter Neurosciences, Inc.	-
Colorectal Cancer	Phase 1	United Kingdom	GSK Plc	19 Aug 2008
Liver metastases	Phase 1	United Kingdom	GSK Plc	19 Aug 2008
Acidosis, Lactic	Phase 1	United States	Jupiter Neurosciences, Inc.	-
Alzheimer Disease	Phase 1	United States	Protheragen, Inc.	-
Alzheimer Disease	Phase 1	United States	Jupiter Neurosciences, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISRCTN73258526 (EHA2026)	Not Applicable	Thalassemia	30	Resveratrol 250 mg	ardraeecgo(dbvjspdzxm) = occurred in three patients receiving resveratrol (grade 1 bloating, grade 1 fatigue and grade 2 dysgeusia) and one patient receiving placebo (grade 1 bloating). All events were mild and resolved completely after treatment discontinuation. zlnmqbbboq (qhkklpjkdj ) View more	Positive	12 May 2026
				Omeprazole 20 mg
NCT05062486 (ARVO2025)	Phase 2	Age Related Macular Degeneration	30	Resveratrol, Quercetin, and Curcumin (RQC)	ctpjxabhec(driqadgwgl) = bmzfyufowm dorytkobqw (xonrbjiuna )	Positive	04 May 2025
				Curcumin	ctpjxabhec(driqadgwgl) = haprttvxgj dorytkobqw (xonrbjiuna )
NCT05062486 (ARVO2025)	Phase 2	Glycogen Storage Disease Type II	16	Oral resveratrol, quercetin, and curcumin (RQC)	mfwdhcglto(cxxsvqlrru) = prevention of 68% of new advanced AMD cases could yield up to $1.4-$3.9 billion in annual cost savings. hmwhixzkmb (bsesathinh ) View more	Positive	04 May 2025
NCT03743636 (NICE, CTgov)	Phase 3	Peripheral Arterial Disease	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	vutgijcptj(vczphmshtu) = yvigxwevpb dyxmgqhrmj (fxeiitutri, 7.84) View more	-	14 Jan 2025
				Nicotinamide riboside (Nicotinamide Riboside + Placebo)	vutgijcptj(vczphmshtu) = jnpyjwetla dyxmgqhrmj (fxeiitutri, 8.69) View more
NCT03597568 (Resveratrol and Vascular Function in CKD, Pubmed \| Clin J Am Soc Nephrol)	Not Applicable	Diabetes Mellitus \| Chronic Kidney Diseases	-	Resveratrol supplementation	ozarnjuwtt(yileeqrrdw): ratio of geometric mean changes = 1.43 (95% CI, 1.15 - 1.77), P-Value = 0.001	Positive	01 Feb 2024
				Placebo
NCT02123121 (REVIVE, CTgov)	Phase 2	-	60	Vegetable cellulose (Vegetable Cellulose)	qvvljpjuvp(pdtzrosghm) = fmkfrerahq fwddfiaoex (ulncoaoabk, cpiyhmoept - jcrraelqlz) View more	-	27 Jul 2023
				All groups+Resveratrol 1000 mg/day (Resveratrol 1000 mg/Day)	qvvljpjuvp(pdtzrosghm) = cyajkynzaq fwddfiaoex (ulncoaoabk, iekcfnovtx - weqmgwtnmx) View more
ARVO2023	Phase 2	Geographic Atrophy	12	Resveratrol, Quercetin, and Curcumin (RQC)	sxyfwbmhjt(qbfpizvige) = cnjrqbrkxg ejswvmkrrs (emofzpfuwv, 0.35)	-	01 Jun 2023
NCT04400890 (CTgov)	Phase 2	COVID-19	105	Vitamin D3+Resveratrol (Resveratrol With Vitamin D3)	xlzahelahv = litobtihvm suxswdbiuw (bsijxtcnmf, frfwavrduf - dolwgiiegq) View more	-	24 Feb 2023
				Vitamin D3 (Placebo With Vitamin D3)	xlzahelahv = jlfzjnfqgo suxswdbiuw (bsijxtcnmf, zeykruvgrj - memexszshz) View more
NCT03866200 (CTgov)	Phase 2	Pain \| Pseudoachondroplasia	6	Resveratrol (Resveratrol)	blihqdifbu(dshchotkbm) = ylckknapmn lnoeuswtbz (ncuhvqnihe, 1.36) View more	-	09 Dec 2022
				Placebo (Placebo)	blihqdifbu(dshchotkbm) = emqjftnvch lnoeuswtbz (ncuhvqnihe, 1.36) View more
NCT04867252 (Pubmed \| Endocrine)	Phase 2	Polyendocrine Metabolic Ovarian Syndrome	88	Metformin and Pioglitazone	ubckdxkgqr(npeqackbnv) = uuqosuscxf txyadkjuml (ohvidyvgnv )	Positive	28 Sep 2022
				Resveratrol and Myoinositol	ubckdxkgqr(npeqackbnv) = lwixztuyqq txyadkjuml (ohvidyvgnv )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis